126 related articles for article (PubMed ID: 9435854)
1. Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.
Graziano RF; Goldstein J; Sundarapandiyan K; Somasundaram C; Keler T; Deo YM
Cancer Immunol Immunother; 1997; 45(3-4):124-7. PubMed ID: 9435854
[No Abstract] [Full Text] [Related]
2. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.
Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM
J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006
[TBL] [Abstract][Full Text] [Related]
3. A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics.
Heijnen IA; Van de Winkel JG
J Hematother; 1995 Oct; 4(5):351-6. PubMed ID: 8581368
[TBL] [Abstract][Full Text] [Related]
4. Amino-terminal charge affects the periplasmic accumulation of recombinant heregulin/EGF hybrids exported using the Escherichia coli alkaline phosphatase signal sequence.
Campion SR; Elsasser E; Chung R
Protein Expr Purif; 1997 Aug; 10(3):331-9. PubMed ID: 9268680
[TBL] [Abstract][Full Text] [Related]
5. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.
van Faassen H; Jo DH; Ryan S; Lowden MJ; Raphael S; MacKenzie CR; Lee SH; Hussack G; Henry KA
Mol Pharm; 2021 Jun; 18(6):2375-2384. PubMed ID: 33999642
[TBL] [Abstract][Full Text] [Related]
7. The EGF receptor binding of recombinant heregulinbeta1/EGF hybrids is blocked by heregulin residue glutamate 195.
Chau BN; Nandagopal K; Niyogi SK; Campion SR
Biochem Biophys Res Commun; 1996 Dec; 229(3):882-6. PubMed ID: 8954988
[TBL] [Abstract][Full Text] [Related]
8. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Stockmeyer B; Berens C; Oduncu FS; Mackensen A; Fey GH
MAbs; 2012; 4(1):45-56. PubMed ID: 22327429
[TBL] [Abstract][Full Text] [Related]
9. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired.
Baulida J; Kraus MH; Alimandi M; Di Fiore PP; Carpenter G
J Biol Chem; 1996 Mar; 271(9):5251-7. PubMed ID: 8617810
[TBL] [Abstract][Full Text] [Related]
10. The structural basis for the specificity of epidermal growth factor and heregulin binding.
Barbacci EG; Guarino BC; Stroh JG; Singleton DH; Rosnack KJ; Moyer JD; Andrews GC
J Biol Chem; 1995 Apr; 270(16):9585-9. PubMed ID: 7721889
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
12. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
Lu D; Zhu Z
Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
Landgraf R; Pegram M; Slamon DJ; Eisenberg D
Biochemistry; 1998 Mar; 37(9):3220-8. PubMed ID: 9485477
[TBL] [Abstract][Full Text] [Related]
14. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein.
Chandler LA; Sosnowski BA; McDonald JR; Price JE; Aukerman SL; Baird A; Pierce GF; Houston LL
Int J Cancer; 1998 Sep; 78(1):106-11. PubMed ID: 9724101
[TBL] [Abstract][Full Text] [Related]
16. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
17. Targeting of adenoviral vectors through a bispecific single-chain antibody.
Haisma HJ; Grill J; Curiel DT; Hoogeland S; van Beusechem VW; Pinedo HM; Gerritsen WR
Cancer Gene Ther; 2000 Jun; 7(6):901-4. PubMed ID: 10880021
[TBL] [Abstract][Full Text] [Related]
18. Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.
Haagen IA; Geerars AJ; Clark MR; van de Winkel JG
J Immunol; 1995 Feb; 154(4):1852-60. PubMed ID: 7836769
[TBL] [Abstract][Full Text] [Related]
19. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
20. Ligand-directed retroviral targeting of human breast cancer cells.
Han X; Kasahara N; Kan YW
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9747-51. PubMed ID: 7568210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
